Active Volume Stock: Teva Pharmaceutical Industries Limited (TEVA)

Tammy Harvey
August 5, 2017

Cantor Fitzgerald's price target would suggest a potential upside of 13.68% from the company's current price.

TEVA has been the subject of several research reports. Analysts reported that the Price Target for Teva Pharmaceutical Industries Limited might touch $50 high while the Average Price Target and Low price Target is $37.59 and $28 respectively. The stock of Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has "Equal Weight" rating given on Tuesday, January 31 by Barclays Capital. Credit Suisse Group set a $39.00 target price on Teva Pharmaceutical Industries Limited and gave the company a "buy" rating in a research report on Thursday. Finally, BidaskClub upgraded shares of Teva Pharmaceutical Industries Limited from a "hold" rating to a "buy" rating in a research note on Wednesday, July 5th. "Ultimately, through all this investigation into the company's performance the analyst decides whether their stock is a "buy", sell" or hold". The stock had a trading volume of 62,024,408 shares. Now moving toward intermediate time frame, 50-day Moving average is more useful at showing position trading trends lasting 50 days. The company has a market cap of $32.86 billion, a PE ratio of 414.62 and a beta of 0.47. Teva Pharmaceutical Industries Limited has a one year low of $20.41 and a one year high of $55.79. National Pension Service raised its position in Teva Pharmaceutical Industries Limited by 15.6% in the second quarter.

Teva Pharmaceutical Industries Limited (TEVA) surprised the stock market in its last reported earnings when it earned $1.06 a piece versus the consensus-estimated $1.03. The return on equity ratio or ROE stands at 4 percent while most common profitability ratio return on investment (ROI) was 3.6 percent. On a currency-neutral basis, this figure rose 17% year over year, but it came up shy of the $5.72 billion in revenue that Wall Street had expected.

The company said it posted a net loss of $6 billion for the quarter, compared to a net income of $188 million in the same period a year earlier.

Peterburg said instability in the Venezuelan bolivar had a material effect, reducing revenue by $183 million compared to the same quarter a year ago.

Now the shares of Teva Pharmaceutical Industries Limited (TEVA) has the trading volume of 106.5 Million shares with the average trading volume of 18290 shares.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. The legal version of this article can be accessed at Schulhoff & Co. Inc. now owns 11,601 shares of the company's stock worth $372,000 after buying an additional 1,004 shares during the last quarter.

The stock of Black Diamond Inc (NASDAQ:BDE) hit a new 52-week high and has $7.67 target or 8.00% above today's $7.10 share price. However, McClellan warned, the company may "face a risk in breaching these covenants" should the dollar continue to depreciate against the euro and the Japanese yen, and Teva fails to raise enough proceeds from the sale of assets. Moreover, Landscape Capital Management L.L.C. has 0.15% invested in the company for 85,013 shares. Inc. boosted its stake in Teva Pharmaceutical Industries by 0.4% in the first quarter. The forecast of 10 surveyed investment analysts covering the stock advises investors to Buy stake in the company.

Teva has been in hot water since February, when former CEO Erez Vigodman stepped down suddenly at what was already an unsteady time for the company. R&D expenses for specialist medicines increased from $235 million in the second quarter of 2016 to $250 million in the second quarter of this year, a 6% increase, mainly due to development expenses for products in the advanced development stages for treatment of fremanezumab and fasinumab.

Other reports by Ligue1talk

Discuss This Article